179 related articles for article (PubMed ID: 30586008)
41. Efficacy of combining pentoxiphylline and vitamin E versus vitamin E alone in non-alcoholic steatohepatitis- A randomized pilot study.
Kedarisetty CK; Bhardwaj A; Kumar G; Rastogi A; Bihari C; Kumar M; Sarin SK
Indian J Gastroenterol; 2021 Feb; 40(1):41-49. PubMed ID: 33772456
[TBL] [Abstract][Full Text] [Related]
42. Association of changes in histologic severity of nonalcoholic steatohepatitis and changes in patient-reported quality of life.
Heath L; Aveyard P; Tomlinson JW; Cobbold JF; Koutoukidis DA
Hepatol Commun; 2022 Oct; 6(10):2623-2633. PubMed ID: 35903833
[TBL] [Abstract][Full Text] [Related]
43. Relationship between resolution of non-alcoholic steatohepatitis and changes in lipoprotein sub-fractions: a post-hoc analysis of the PIVENS trial.
Corey KE; Wilson LA; Altinbas A; Yates KP; Kleiner DE; Chung RT; Krauss RM; Chalasani N;
Aliment Pharmacol Ther; 2019 May; 49(9):1205-1213. PubMed ID: 30854694
[TBL] [Abstract][Full Text] [Related]
44. Haptoglobin genotype and cardiovascular outcomes in diabetes mellitus - natural history of the disease and the effect of vitamin E treatment. Meta-analysis of the medical literature.
Vardi M; Blum S; Levy AP
Eur J Intern Med; 2012 Oct; 23(7):628-32. PubMed ID: 22939808
[TBL] [Abstract][Full Text] [Related]
45. Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study.
Harrison SA; Alkhouri N; Davison BA; Sanyal A; Edwards C; Colca JR; Lee BH; Loomba R; Cusi K; Kolterman O; Cotter G; Dittrich HC
J Hepatol; 2020 Apr; 72(4):613-626. PubMed ID: 31697972
[TBL] [Abstract][Full Text] [Related]
46. Pharmacogenomic effect of vitamin E on kidney structure and function in transgenic mice with the haptoglobin 2-2 genotype and diabetes mellitus.
Nakhoul FM; Miller-Lotan R; Awad H; Asleh R; Jad K; Nakhoul N; Asaf R; Abu-Saleh N; Levy AP
Am J Physiol Renal Physiol; 2009 Apr; 296(4):F830-8. PubMed ID: 19176700
[TBL] [Abstract][Full Text] [Related]
47. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Cusi K; Orsak B; Bril F; Lomonaco R; Hecht J; Ortiz-Lopez C; Tio F; Hardies J; Darland C; Musi N; Webb A; Portillo-Sanchez P
Ann Intern Med; 2016 Sep; 165(5):305-15. PubMed ID: 27322798
[TBL] [Abstract][Full Text] [Related]
48. Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes.
Ahmed A; Wong RJ; Harrison SA
Clin Gastroenterol Hepatol; 2015 Nov; 13(12):2062-70. PubMed ID: 26226097
[TBL] [Abstract][Full Text] [Related]
49. Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design.
Friedman S; Sanyal A; Goodman Z; Lefebvre E; Gottwald M; Fischer L; Ratziu V
Contemp Clin Trials; 2016 Mar; 47():356-65. PubMed ID: 26944023
[TBL] [Abstract][Full Text] [Related]
50. Interactions of allelic variance of PNPLA3 with nongenetic factors in predicting nonalcoholic steatohepatitis and nonhepatic complications of severe obesity.
Guichelaar MM; Gawrieh S; Olivier M; Viker K; Krishnan A; Sanderson S; Malinchoc M; Watt KD; Swain JM; Sarr M; Charlton MR
Obesity (Silver Spring); 2013 Sep; 21(9):1935-41. PubMed ID: 23418085
[TBL] [Abstract][Full Text] [Related]
51. Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies.
Reddy YK; Marella HK; Jiang Y; Ganguli S; Snell P; Podila PSB; Maliakkal B; Satapathy SK
J Clin Exp Hepatol; 2020; 10(3):245-254. PubMed ID: 32405181
[TBL] [Abstract][Full Text] [Related]
52. Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial.
Ratziu V; de Guevara L; Safadi R; Poordad F; Fuster F; Flores-Figueroa J; Arrese M; Fracanzani AL; Ben Bashat D; Lackner K; Gorfine T; Kadosh S; Oren R; Halperin M; Hayardeny L; Loomba R; Friedman S; ; Sanyal AJ
Nat Med; 2021 Oct; 27(10):1825-1835. PubMed ID: 34621052
[TBL] [Abstract][Full Text] [Related]
53. PNPLA3 genotype increases susceptibility of nonalcoholic steatohepatitis among obese patients with nonalcoholic fatty liver disease.
Tai CM; Huang CK; Tu HP; Hwang JC; Chang CY; Yu ML
Surg Obes Relat Dis; 2015; 11(4):888-94. PubMed ID: 25240529
[TBL] [Abstract][Full Text] [Related]
54. Association Between Magnetic Resonance Imaging-Proton Density Fat Fraction and Liver Histology Features in Patients With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis.
Wildman-Tobriner B; Middleton MM; Moylan CA; Rossi S; Flores O; Chang ZA; Abdelmalek MF; Sirlin CB; Bashir MR
Gastroenterology; 2018 Nov; 155(5):1428-1435.e2. PubMed ID: 30031769
[TBL] [Abstract][Full Text] [Related]
55. Effect of pharmacological interventions and placebo on liver Histology in nonalcoholic steatohepatitis: A network meta-analysis.
Pennisi G; Celsa C; Enea M; Vaccaro M; Di Marco V; Ciccioli C; Infantino G; La Mantia C; Parisi S; Vernuccio F; Craxì A; Cammà C; Petta S
Nutr Metab Cardiovasc Dis; 2022 Oct; 32(10):2279-2288. PubMed ID: 35970684
[TBL] [Abstract][Full Text] [Related]
56. Systematic review with meta-analysis: The effect of vitamin E supplementation in adult patients with non-alcoholic fatty liver disease.
Vadarlis A; Antza C; Bakaloudi DR; Doundoulakis I; Kalopitas G; Samara M; Dardavessis T; Maris T; Chourdakis M
J Gastroenterol Hepatol; 2021 Feb; 36(2):311-319. PubMed ID: 32810309
[TBL] [Abstract][Full Text] [Related]
57. Vitamin E Intake Is Associated with Lower Brain Volume in Haptoglobin 1-1 Elderly with Type 2 Diabetes.
Livny A; Schnaider Beeri M; Heymann A; Moshier E; Berman Y; Mamistalov M; Shahar DR; Tsarfaty G; Leroith D; Preiss R; Soleimani L; Silverman JM; Bendlin BB; Levy A; Ravona-Springer R
J Alzheimers Dis; 2020; 74(2):649-658. PubMed ID: 32065799
[TBL] [Abstract][Full Text] [Related]
58. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial.
Zein CO; Yerian LM; Gogate P; Lopez R; Kirwan JP; Feldstein AE; McCullough AJ
Hepatology; 2011 Nov; 54(5):1610-9. PubMed ID: 21748765
[TBL] [Abstract][Full Text] [Related]
59. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.
Friedman SL; Ratziu V; Harrison SA; Abdelmalek MF; Aithal GP; Caballeria J; Francque S; Farrell G; Kowdley KV; Craxi A; Simon K; Fischer L; Melchor-Khan L; Vest J; Wiens BL; Vig P; Seyedkazemi S; Goodman Z; Wong VW; Loomba R; Tacke F; Sanyal A; Lefebvre E
Hepatology; 2018 May; 67(5):1754-1767. PubMed ID: 28833331
[TBL] [Abstract][Full Text] [Related]
60. Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype.
Blum S; Vardi M; Brown JB; Russell A; Milman U; Shapira C; Levy NS; Miller-Lotan R; Asleh R; Levy AP
Pharmacogenomics; 2010 May; 11(5):675-84. PubMed ID: 20415560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
